Ranibizumab biosimilar(Rubin Ltd)

Zentiva will manage commercial activities primarily within Europe and CIS markets, excluding the US and Canada. Credit: Zentiva Group, a.s. Zentiva Group has entered into a licence and supply agreement with pharmaceutical company Lupin for the commercialisation of the latter’s biosimilar Certolizumab Pegol, a tumour necrosis factor alpha (TNFα) inhibitor medicine, across several markets. The partnership will enhance the availability of the affordable biosimilar on a global scale. Zentiva will manage commercial activities primarily within Europe and CIS markets, excluding the US and Canada. Meanwhile, Lupin will focus on product development, manufacturing, supply of the medicine within the agreed territories and commercial efforts in the remaining regions, including Canada and the US. The collaboration involves investment from both companies. Lupin will receive $10m upon execution of the agreement and could earn up to $50m based on developmental and regulatory milestones. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Profits generated within their respective markets will be shared between Zentiva and Lupin. The biosimilar is a recombinant humanised antibody Fab’ fragment targeting TNFα, conjugated to a 40kDa polyethylene glycol. Zentiva CEO Steffen Saltofte stated: “Ensuring accessibility to high-quality and affordable healthcare is at Zentiva’s core. Our collaboration agreement with Lupin signifies another step forward in our biosimilars and growth strategies. “Lupin’s advanced development and manufacturing capabilities, coupled with our significant market knowledge and presence, mean we can deliver high-quality biosimilar solutions for our customers and their patients, aligning with our purpose of providing health and wellbeing for all generations.” The biosimilar is indicated for conditions including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis without X-ray evidence (non-radiographic), moderate-to-severe plaque psoriasis and Crohn’s disease. Lupin president of corporate development Fabrice Egros stated: “Our global development and commercialisation partnership with Zentiva, with its pan-European focus, enables Lupin to commercialise this unique biosimilar in its core markets and through Zentiva in Europe. “This partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions and ensuring accessibility and affordability of transformative therapies worldwide.” In March 2025, Lupin entered a licensing and supply agreement with SteinCares to commercialise its biosimilar ranibizumab in Latin American markets excluding Argentina and Mexico. Pharmaceutical Technology Excellence Awards - Have you nominated? Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact . This is your chance to showcase your achievements, highlight industry advancements , and gain global recognition . Don't miss the opportunity to be honoured among the best - submit your nomination today! Nominate Now

Mumbai: Generics drug maker, Lupin has outlicensed its retinal disorder biosimilar ‘ ranibizumab ’ Latin America commercial rights (excluding Mexico and Argentina) to a healthcare company SteinCares . In a stock exchange filing Lupin announced that it has entered into a license and supply agreement with SteinCares, a healthcare company for commercialisation of the company’s biosimilar ranibizumab across Latin America excluding Mexico and Argentina. Under the terms of the agreement, Lupin will be responsible for manufacturing the drug and the other partner SteinCares will handle all regulatory filings, registrations and commercialization of the same across the markets. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A), that helps to prevent abnormal blood vessel growth and leakage in the retina, which is central to treating retinal disorders. Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV), the release stated. The drug is a biosimilar to Lucentis marketed by Genentech , a subsidiary of Swiss drugmaker Roche and Lupin has been marketing its ranibizumab biosimilar in India under the brand name RaniEyes since 2022. “Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients,” Dr Cyrus Karkaria, President Biotechnology , Lupin commented. “We have consistently been first to market products from highly regulated markets across several countries in the region. Our presence has translated into significant cost savings, driven by decades of experience and a deep understanding of Latin America’s healthcare landscape,” Sebastián Katz, Chief Strategy Officer, SteinCares added. By Online Bureau ,